1. Home
  2. GYRE

GYRE

Gyre Therapeutics Inc.

Logo Gyre Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Founded: 2002 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 1.5B IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 80.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.41 EPS Growth: N/A
52 Week Low/High: $3.00 - $30.40 Next Earning Date: 04-30-2024
Revenue: $113,450,000 Revenue Growth: 10.91%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: